hotspot -WSS

hotspot

author：comprehensive 2025-09-07 04:12:52 - browse：83894

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： U.K. sequencing study surfaces new findings about tumor DNA

WSS

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Ahead of JPM, here's who's profiting most in health care

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How a scoliosis diagnosis changed the life of one young dancer

Hollywood unions extend contract negotiations for actors

Antibiotic resistance and the global rise in human conflict

hotspot

hotspot

The next ALS data readout — overdue but important

hotspot

In age of alternative facts, a scholarly course on calling out crap

GSK Flovent asthma inhalers replaced by authorized generics

Jerome Adams on the need for new antivirals for Covid

J&J to buy cancer drug developer Ambrx Biopharma

Medicare proposal to cover medical devices draws a mixed reaction

Bright Health sells Medicare Advantage business to Molina

Peter Hotez and the public health issue of online harassment

Medicare proposal to cover medical devices draws a mixed reaction

United colonoscopy coverage change 'may cost lives,' doctors say

Medical leaders decry Supreme Court decision on affirmative action

leisure time

U.K. sequencing study surfaces new findings about tumor DNA

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Hollywood unions extend contract negotiations for actors

Virginia high school admissions case could be legal follow

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

State Dept. review finds Biden bears some blame for Afghanistan failures

entertainment

focus

explore

explore